Skip to content

Effect of Remazolam Toluenesulfonic Acid at Different Concentrations in Local Anesthesia Operation in Hypertensive Ophthalmic Patients

Effect of Remazolam Toluenesulfonic Acid at Different Concentrations in Local Anesthesia Operation in Hypertensive Ophthalmic Patients

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100045515
Enrollment
Unknown
Registered
2021-04-18
Start date
2021-05-01
Completion date
Unknown
Last updated
2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

R1 group:0.05mg. kg^-1. h-1 Rimazolam
R2 group:0.1mg. kg^-1. H-1 Rimazolam
R3 group:0.15mg. kg^-1. H-1 Rimazolam

Sponsors

The First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 70 Years

Inclusion criteria

Inclusion criteria: A total of 80 hypertensive patients (SBP>=140mmHg or DBP>=90mmHg after admission, requiring controlled hypotension) who underwent ophthalmic surgery under retrobulbar nerve block anesthesia in our hospital from April 2021 to May 2021 were selected. They had hypertension grade 1~3, ASA grade I~II, aged 40~70 years old, regardless of gender.

Exclusion criteria

Exclusion criteria: 1.Patients allergic to benzodiazepines or dexmedetomidine; 2.Schizophrenia, epilepsy, Parkinson's disease and other neuropsychiatric diseases before surgery; 3.Any cerebrovascular accidents, such as stroke and transient ischemic attack (TIA), occurred within 3 months; 4.History of abuse of sedatives, antidepressants, psychoactive drugs, and alcoholism; 5.Severe impairment of liver and kidney and other important organs; 6.Other researchers consider it inappropriate to include in the study.

Design outcomes

Secondary

MeasureTime frame
Heart rate;Pulse oxygen saturation;

Primary

MeasureTime frame
Blood pressure;

Countries

China

Contacts

Public ContactSun Zhentao

The First Affiliated Hospital of Zhengzhou University

gentlesun@126.com+86 13603455483

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026